TY - JOUR
T1 - Umbilical Cord Blood Transplants
T2 - Current Status and Evolving Therapies
AU - Gupta, Ashish O.
AU - Wagner, John E.
N1 - Publisher Copyright:
© Copyright © 2020 Gupta and Wagner.
PY - 2020/10/2
Y1 - 2020/10/2
N2 - Hematopoietic cell transplants using stem cells from umbilical cord blood are used worldwide for the treatment of malignant and non-malignant disorders. Transplant procedures from this stem cell source have shown promising outcomes in successfully treating various hematologic, immunologic, malignant, and inherited metabolic disorders. Rapid availability of these stem cells is an important advantage over other unrelated donor transplants, especially in situations where waiting can adversely affect the prognosis. The umbilical cord blood is rich in CD34+ stem cells, though with a limited cell dose and usually takes longer to engraft. Limitations around this have been addressed by in vivo and ex vivo expansion techniques as well as enhanced engraftment kinetics. Development of adoptive immunotherapy using other components of umbilical cord blood such as regulatory T cells, virus-specific T cells, and natural killer cells has further transformed the field and enhanced the utility of umbilical cord blood unit.
AB - Hematopoietic cell transplants using stem cells from umbilical cord blood are used worldwide for the treatment of malignant and non-malignant disorders. Transplant procedures from this stem cell source have shown promising outcomes in successfully treating various hematologic, immunologic, malignant, and inherited metabolic disorders. Rapid availability of these stem cells is an important advantage over other unrelated donor transplants, especially in situations where waiting can adversely affect the prognosis. The umbilical cord blood is rich in CD34+ stem cells, though with a limited cell dose and usually takes longer to engraft. Limitations around this have been addressed by in vivo and ex vivo expansion techniques as well as enhanced engraftment kinetics. Development of adoptive immunotherapy using other components of umbilical cord blood such as regulatory T cells, virus-specific T cells, and natural killer cells has further transformed the field and enhanced the utility of umbilical cord blood unit.
KW - alternative use of UCB
KW - cord expansion
KW - cord selection
KW - immune effector function
KW - umbical cord stem cells (UCSC)
UR - http://www.scopus.com/inward/record.url?scp=85092939981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092939981&partnerID=8YFLogxK
U2 - 10.3389/fped.2020.570282
DO - 10.3389/fped.2020.570282
M3 - Review article
C2 - 33123504
AN - SCOPUS:85092939981
SN - 2296-2360
VL - 8
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 570282
ER -